Abstract MPTH75: Linking Pulmonary Function Decline and Cardiovascular Disease Risk via Plasma Proteomics

Y Yura Lee (Department of Biomedical Sciences Graduate School of Medical Science Brain Korea 21 Project Yonsei University College of Medicine Seoul Republic of Korea) T Thomas Austin (UNIVERSITY WASHINGTON, Shoreline, Washington, United States) T Traci Bartz (University of Washington, Seattle, Washington, United States) C Christine Ladd-Acosta (Johns Hopkins University, Baltimore, Maryland, United States) A Alanna Morrison (University of Texas Health Science Center at Houston, School of Public Health, Houston, Texas, United States) K Kari North (UNIV OF TX HEALTH SCI CTR HOUSTON, Houston, Texas, United States) E Eric Boerwinkle A Amil Shah (University of Texas Southwestern Medical Center, Dallas (A.S.).) B Bruce Psaty (University of Washington, Seattle, WA, USA.) S Sina Gharib (UNIVERSITY WASHINGTON, Shoreline, Washington, United States) S Stephanie London (NIEHS, Research Triangle Park, North Carolina, United States) B Bing Yu (College of Chemistry and Materials Science, Guangdong Provincial Key Laboratory of Supramolecular Coordination Chemistry)

Abstract

Background: Pulmonary function decline is associated with an increased risk of cardiovascular disease (CVD), yet the underlying molecular mechanisms remain unclear. We aimed to identify plasma proteins associated with forced expiratory volume in one second (FEV1) decline and subsequent CVD risk and to uncover their shared molecular mechanisms. Methods: Spirometric measurements of FEV1 were collected at visits 2 (1990–92) and 5 (2011–13) in the Atherosclerosis Risk in Communities (ARIC) Study for discovery, and at years 6 (1993–94) and 18 (2005–06) in the Cardiovascular Health Study (CHS) for replication ( Figure 1 ). Plasma proteomics (5K SomaScan) were assayed at baseline for each cohort. Annualized FEV1 decline was assessed using linear regression, adjusting for age, sex, race, smoking, BMI, kidney function, and baseline FEV1. Proteins associated with FEV1 decline were examined for incident coronary heart disease (CHD), heart failure (HF), and all-cause mortality, adjusting for clinical risk factors. Colocalization analyses were performed to assess shared genetic architecture between replicated proteins, FEV1, and clinical outcomes. Results: Among 4,766 proteins, 24 were associated with FEV1 decline (FDR<0.05) in ARIC (N = 3,435; baseline mean age: 54 years; 18% Black; 58% female). Of these, eleven were associated with incident CHD, 20 with HF, and 21 with mortality (FDR<0.05) ( Figure 2A ). Of the 24 proteins from ARIC, 20 (83%) displayed consistent directional effects with FEV1 decline in CHS (N = 663; baseline mean age: 85 years; 16% Black; 64% female) ( Figure 2B ). Five proteins showed robust replication associations across all outcomes (FDR < 0.05): CA2D3 and OMGP demonstrated risk-decreasing effects, whereas GBRL1, Apo F, and lectin, mannose-binding 2 indicated risk-increasing effects ( Figure 2C ). Colocalization analyses showed that Apo F and FEV1, and Apo F and CHD shared the same underlying causal variants (posterior probabilities>0.7). Conclusion: We identified and replicated plasma proteins, notably Apo F, linking pulmonary function decline to cardiovascular outcomes, offering insight into shared molecular mechanisms of cardiopulmonary disorders and providing potential intervention targets.

Article Details

Journal Circulation
Volume / Issue Vol. 153, Issue Suppl_1
Published March 24, 2026
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (12)

Y

Yura Lee

Department of Biomedical Sciences Graduate School of Medical Science Brain Korea 21 Project Yonsei University College of Medicine Seoul Republic of Korea

T

Thomas Austin

UNIVERSITY WASHINGTON, Shoreline, Washington, United States

T

Traci Bartz

University of Washington, Seattle, Washington, United States

C

Christine Ladd-Acosta

Johns Hopkins University, Baltimore, Maryland, United States

A

Alanna Morrison

University of Texas Health Science Center at Houston, School of Public Health, Houston, Texas, United States

K

Kari North

UNIV OF TX HEALTH SCI CTR HOUSTON, Houston, Texas, United States

E

Eric Boerwinkle

A

Amil Shah

University of Texas Southwestern Medical Center, Dallas (A.S.).

B

Bruce Psaty

University of Washington, Seattle, WA, USA.

S

Sina Gharib

UNIVERSITY WASHINGTON, Shoreline, Washington, United States

S

Stephanie London

NIEHS, Research Triangle Park, North Carolina, United States

B

Bing Yu

College of Chemistry and Materials Science, Guangdong Provincial Key Laboratory of Supramolecular Coordination Chemistry